<DOC>
	<DOC>NCT00910247</DOC>
	<brief_summary>This is a long term, open-label, safety extension study in subjects with partial onset seizures.</brief_summary>
	<brief_title>Eslicarbazepine Acetate Monotherapy Long Term Study</brief_title>
	<detailed_description>This is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of continuing study drug treatment post 1 year until a subject discontinues study, the study drug becomes clinically available in the subject's locale, or the sponsor terminates the study drug clinical development program. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Subject Inclusion/ Subject who completed, exited, or discontinued for reasons other than safety from the 18week treatment phase of Protocols 093045 or 093046 and are willing to continue participation in this study are eligible. Subject must have completed at least the first 3 weeks of the 18week doubleblind treatment period of Protocols 093045 or 093046 to be eligible. Subject must give written informed consent prior to participation in the study. For subjects &lt;18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. All subjects must sign privacy authorization form, if applicable. All females of child bearing potential (â‰¤65 years of age) must also sign the "Women of Childbearing Potential" Addendum. Subjects must, in the opinion of the Investigator (with consultation with Medical Monitor as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation. If female subject, must continue the accepted method of birth control defined in Protocols 093045 or 093046 for the duration of this study as well Criterion for Continuation into the Post 1 year Part of Study: For subjects to continue into the post 1 year part of the study, subjects must, in the opinion of the Investigator (with consultation with Medical Monitor, as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Anticonvulsant</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Epilepsy with simple or complete partial onset seizures</keyword>
</DOC>